A real-world paramedic case study of acute COPD exacerbation featuring oxygen strategies, bronchodilators, magnesium, CPAP considerations, and critical on-scene decisions.

Case Study Introduction

The patient is a 68-year-old man with a history of Chronic Obstructive Pulmonary Disease (COPD), diagnosed five years ago. He has a 40-pack-year smoking history but quit three years ago. He presented with increasing shortness of breath over the past 24 hours, a productive cough with yellow sputum, and wheezing. When primary care paramedics arrived, the patient was visibly distressed. His respiratory rate was 28 breaths per minute, and pulse oximetry showed an oxygen saturation (SpO2) of 82% on room air. He was using accessory muscles to breathe and unable to speak in full sentences, indicating a severe COPD exacerbation.

A student paramedic was riding with the primary care paramedic (PCP) crew and initiated treatment with a Ventolin (salbutamol) nebulizer. After 15 minutes, the patient showed limited improvement; his breathing remained laboured and oxygen saturation showed minimal increase. The patient’s small, cluttered apartment was extremely cramped, allowing only one responder at a time to access him, which complicated the intervention.

Advanced care paramedics (ACPs) arrived and, noting his worsening condition, moved him to the living room for more space. The ACP suggested rolling him in his wheeled office chair, but the patient preferred to walk. During transfer, he appeared weak and anxious, struggling to breathe, but paramedics supported him to the couch.

COPD Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disorder mainly caused by exposure to harmful particles, especially cigarette smoke. It consists of two primary conditions: chronic bronchitis and emphysema. Both affect how air flows in and out of the lungs, leading to breathing difficulties. (Barberà and I. Blanco)

Chronic bronchitis involves inflammation and swelling of the bronchial tubes, triggering increased mucus production that clogs the airways and narrows the bronchial passages, making breathing difficult. Persistent coughing and sputum production are common symptoms.

Emphysema damages the alveoli—the tiny air sacs where oxygen and carbon dioxide are exchanged. Normally, alveoli are elastic, expanding and contracting with each breath. Emphysema destroys the walls between alveoli, causing them to lose their elasticity.

What does it actually mean to say emphysema destroys the walls between alveoli and causes them to lose their elasticity?

It means that the disease physically damages and breaks down the thin walls that separate the alveoli. In healthy lungs, alveoli resemble small, elastic balloons that inflate and deflate with each breath. Emphysema breaks down the walls between adjacent alveoli, causing them to merge into larger, irregular air spaces. This reduces the total surface area available for oxygen and carbon dioxide exchange, leading to shortness of breath and fatigue.

Healthy alveoli possess elasticity, allowing them to spring back to their original size after stretching and aiding in expelling air during exhalation. The breakdown of this elasticity results from damage to elastic fibers (elastin) and structural proteins (collagen), diminishing the lung tissue’s ability to rebound. Consequently, the lungs lose their elasticity and can’t fully regain their shape. When this happens, air becomes trapped, alveoli do not empty efficiently, and stale air accumulates.

Smoking is the leading risk factor for COPD. The chemicals in cigarette smoke cause chronic airway inflammation and oxidative stress, leading to accelerated lung damage. (Churg et al.) In this patient’s case, a 40-pack-year smoking history played a significant role in both the development and progression of his disease. Although he quit smoking three years ago, the previously sustained damage continues to affect his lung function.

Exacerbations—sudden worsening of symptoms—are common in COPD. They are typically triggered by infections or environmental irritants. During an exacerbation, inflammation increases, airflow obstruction worsens, and gas exchange diminishes further. This patient’s recent development of increased shortness of breath, a productive cough with yellow sputum, and wheezing fits this pattern.

Clinically, COPD patients often present with a chronic cough, sputum production, and progressively worsening breathlessness. During exacerbations, these symptoms intensify, and signs of respiratory distress become more apparent. The use of accessory muscles, increased respiratory rate, difficulty speaking in full sentences, and low oxygen saturation all indicate a severe exacerbation, as observed in this patient.

Management of stable COPD typically includes smoking cessation, inhaled bronchodilators, corticosteroids, and pulmonary rehabilitation to improve symptoms and quality of life. During acute exacerbations, treatment focuses on relieving airway obstruction and improving oxygenation. This involves nebulized bronchodilators, corticosteroids, antibiotics if an infection is present, and controlled oxygen therapy.

Understanding this pathophysiology explains the patient’s poor response to initial Ventolin therapy alone and highlights the need for additional interventions to manage his severe exacerbation.

Advanced Care Interventions

Once the patient was moved to the couch, the ACPs immediately reassessed him. His breathing remained laboured, accessory muscle use persisted, and oxygen saturation had only slightly improved despite the initial Ventolin nebulizer.

While the attending ACP was assessing the patient, another provider added ipratropium bromide to the nebulizer. When the PCP student inquired about this, he explained, “The airway obstruction isn’t relieved by salbutamol alone. So, I’ve added ipratropium bromide (Atrovent) to target different receptors.”

Ipratropium is an anticholinergic bronchodilator that blocks the parasympathetic nervous system, helping relax airway muscles and reduce mucus secretion. Both nebulized Ventolin (a beta-2 agonist) and ipratropium were administered concurrently. This combination therapy produces greater bronchodilation than either drug alone.

However, after several minutes, the patient showed minimal improvement, indicating severe and refractory bronchospasm. The ACP team discussed next steps; one member suggested administering intravenous magnesium sulfate and explained to the student, “Magnesium sulfate acts as a smooth muscle relaxant and can help when traditional bronchodilators don’t fully open the airways.”

Some studies have shown that IV magnesium sulfate can reduce airway muscle contraction during acute exacerbations of COPD. (Moradi et al.). (Rowe et al.) (Gourgoulianis et al.) The paramedics established IV access and began the magnesium sulfate infusion while continuously monitoring the patient’s respiratory status and oxygen saturation.

Throughout treatment, the paramedics communicated closely with the patient, explaining each step to help reduce anxiety. They noted the patient remained weak and anxious, requiring gentle reassurance. The patient stated, “I’m struggling to catch my breath… it feels like I can’t get enough air.”

To help manage this, the paramedics kept the environment calm, encouraged slow breathing, and monitored vital signs closely.

Oxygen delivery was adjusted to maintain saturation between 88-92%, thus avoiding the risk of worsening hypercapnia, which can occur in COPD exacerbations if too much oxygen is administered.

The ACPs reassessed after each intervention, observing small but steady clinical improvements: the patient’s respiratory rate decreased slightly, and he appeared less distressed. These changes guided the decision to continue current therapy, monitor closely, and prepare for transport.

Discussion on Oxygenation Strategies

High-flow oxygen therapy is typically the first-line treatment for acute COPD exacerbations presenting with critical hypoxemia to rapidly improve oxygenation. By administering oxygen at higher flow rates, it increases the fraction of inspired oxygen (FiO2), boosting blood oxygen levels. In this case, the patient’s initial SpO2 was 82%, which is critically low, making supplemental oxygen essential to prevent hypoxia.

While caring for the patient, one of the ACPs asked the PCP to monitor oxygen saturation and keep it between 88 and 92%. Later, the student asked, “Why do you seem to be limiting oxygen administration? I was told that ‘knocking out the hypoxic drive’ is no longer the current thinking.”

There is strong evidence that administering excessive oxygen to COPD patients in emergency settings can worsen hypercapnia. When oxygen saturation exceeds 88%–92%, the risk of hypercapnia, respiratory acidosis, and mortality increases in those with acute COPD exacerbations. (Brill and J. A. Wedzicha) (Joosten et al.) (Echevarria et al.) These effects are primarily due to physiological mechanisms such as worsening ventilation-perfusion mismatch and a reduction in hypoxic respiratory drive. Although diminished respiratory drive occurs, is not considered the main cause. (Eschevarria et al.)

“You’re right, there is modest hypoventilation, but it’s usually only slight, and it usually only occurs when oxygen is first administered. It doesn’t fully explain the rise and PaCO2. There are two other things that are probably bigger contributors to the rise in arterial carbon dioxide levels. ”

“The first, and probably the less important of the two is the Haldane effect. The Haldane Effect is just a fancy way of saying that oxygenated haemoglobin has a decreased capacity to carry CO2. So, when oxygen levels rise, haemoglobin dumps the CO2 in the blood and, as a result, you see increased levels of dissolved CO2 or a higher PaCO2.”

“The second- and this is the important part- relates to ‘hypoxic pulmonary vasoconstriction’. That just means that when oxygen levels are low in part of the lung, local vasoconstriction redirects blood to better ventilated areas, optimizing gas exchange. Its a protective mechanism. But, when we flood the lungs with oxygen, there are no low-oxygen areas anymore – even if they’re poorly ventilated. So, we turn this protective mechanism off and worsen the ventilation-perfusion (V/Q) mismatch caused by damaged alveoli. In other words, we force perfusion back to non-functional areas instead of concentrating in the regions that are still functioning well.”

“So, we need some oxygen because he’s critically hypoxic but too much oxygen will actually make his hypercarbia worse!”

Discussion on Nebulized Medications

Nebulized medications often play a role alongside oxygen therapy in the emergency management of COPD. (Suau and P. M. C. DeBlieux) Bronchodilators like Ventolin (salbutamol) and ipratropium work by relaxing and opening constricted airways, improving airflow and enhancing gas exchange in the lungs. (Donohue) Although these are common and standard treatments, it should be noted that there is no high-quality evidence from randomized controlled trials supporting their efficacy (Crisafulli et al.). Nevertheless, simply providing oxygen without addressing the underlying airway obstruction may not adequately relieve the patient’s symptoms or reverse the severity of the exacerbation. For better or worse, nebulized medications remain one of the few tools available to us.

Discussion on Logistics

The case also presents a significant practical challenge: managing patient mobility during treatment. Advanced care paramedics needed to move the patient from his cramped apartment to a more suitable space for care. They recommended using a wheeled chair to reduce exertion, but the patient preferred to walk.

Walking increased the patient’s anxiety and the risk of exhaustion. The paramedics supported him carefully, aware that overexertion could worsen respiratory distress. This situation emphasizes the balance between respecting patient autonomy and ensuring medical safety. Facilitating movement without destabilizing the patient requires good communication, gentle encouragement, and close monitoring.

Best practices for paramedics include:

– Clearly explaining the reasons for assistance to ease patient anxiety.

– Assessing tolerance for movement before and during transfers.

– Providing physical support to minimize energy expenditure.

– Adjusting treatment timing to avoid movement during periods of critical respiratory instability.

In this case, the paramedics successfully moved the patient to the couch for better treatment, though it caused additional distress. A more assertive approach might have been in the patient’s best interest.

Magnesium Sulfate in Acute COPD Exacerbations

Magnesium sulfate is used in some acute respiratory cases for its bronchodilator properties. It works by relaxing smooth muscle in the airways through calcium channel blockade, reducing muscle contraction and airway narrowing. In severe COPD exacerbations, it is considered when traditional bronchodilators are insufficient. The goal is to reduce bronchospasm refractory to initial treatment, thereby improving airflow and easing breathing. (Alzaid et al.)

In this case, paramedics administered intravenous magnesium sulfate after the patient had limited response to nebulized Ventolin and ipratropium. This reflects evidence that magnesium sulfate can relax airway muscles during severe episodes. While clinical outcomes vary, some studies suggest magnesium may reduce hospitalization rates and improve lung function during exacerbations.

Monitoring is critical during administration, as magnesium can affect the cardiovascular and neuromuscular systems. Magnesium sulfate is generally well tolerated in controlled doses, but careful monitoring is needed to avoid side effects such as hypotension or muscle weakness.

Continuous Positive Airway Pressure (CPAP) in COPD Management

CPAP delivers a constant positive pressure to the airways during both inspiration and expiration, helping keep airways open, preventing collapse, and reducing the work of breathing.CPAP is most often used for COPD exacerbations complicated by hypercapnic respiratory failure or signs of respiratory muscle fatigue. It improves ventilation by promoting alveolar recruitment and enhancing gas exchange. (Csoma et al.)

However, patient tolerance is crucial. Masks can cause discomfort, claustrophobia, and anxiety, which may limit cooperation. In this case, the patient was already anxious and struggling, so CPAP risked worsening their distress. As a result, the ACPs chose not to use CPAP initially, though later discussions raised the question of whether using light sedation might have helped. Ketamine was suggested as a good option due to its bronchodilatory effects.

When indicated and tolerated, CPAP can reduce the need for intubation and improve outcomes. The decision to start CPAP requires weighing its benefits against patient comfort, clinical status, and potential risks.

Debate on IM Epinephrine Use

During the case, one of the PCPs suggested, “Could we try IM epinephrine to open those constricted airways quickly?”

Intramuscular (IM) epinephrine is a potent bronchodilator that acts on both alpha- and beta-adrenergic receptors. It relaxes airway smooth muscle via beta-2 stimulation and causes vasoconstriction through alpha receptors, reducing mucosal swelling. Its rapid onset makes it valuable in certain airway obstructions, such as anaphylaxis.

The attending ACP responded, “I’m hesitant. In COPD, especially with emphysema, the problem isn’t just airway constriction—it’s air trapping and damaged alveoli. Epinephrine might worsen air trapping, plus it can increase heart rate and oxygen demand.”

“I understand that the Beta-1 effects could increase heart rate and oxygen demand,” said the PCP, “but how could it worsen air trapping?”

“Well, that’s a good question,” answered the ACP. “Epinephrine’s stimulation of beta-adrenergic receptors can cause bronchodilation but may also increase both the respiratory rate and tidal volume. If respiratory rate rises too much, or expiratory time is shortened, incomplete exhalation leads to air trapping. Some people call it dynamic hyperinflation. Anyway, epinephrine can help in cases like bronchospasm or anaphylaxis but its potential to worsen air trapping in COPD—by increasing respiratory rate and reducing expiratory time—can make things worse.”

Current guidelines do not generally recommend epinephrine for COPD exacerbations unless there is accompanying anaphylaxis or a severe allergic component. In truth, the evidence for using epinephrine in pure COPD exacerbations is limited and often equivocal.(Suau and DeBlieux) COPD pathophysiology primarily involves airflow limitation from mucus, airway inflammation, and loss of elastic recoil—issues epinephrine may not adequately address. Inhaled beta-2 agonists, anticholinergics, corticosteroids, and magnesium sulfate more directly target these mechanisms. 

Alternative strategies include escalating nebulized bronchodilators, adding systemic corticosteroids to reduce inflammation, and providing non-invasive ventilation support such as CPAP if tolerated. Thus, while IM epinephrine has theoretical bronchodilator benefits, it is not a standard treatment for COPD exacerbation due to the risks it carries.

Conclusion and Future Work

This case highlights the complexities involved in managing acute COPD exacerbations in the out-of-hospital setting. Tailored, evidence-based interventions are essential. The patient’s severe respiratory distress required immediate administration of nebulized bronchodilators, careful oxygen titration, and intravenous magnesium sulfate to treat refractory bronchospasm.

Clinical judgment—particularly balancing oxygen therapy to prevent hypercapnia and supporting mobility without causing exhaustion—was crucial. The paramedics communicated clearly with the patient, helping to reduce anxiety during this distressing event.

Challenges remained. The cramped apartment limited treatment space, and the patient’s preference to walk instead of being wheeled posed risks. Movement strategies must prioritize both patient comfort and safety.

Could CPAP have been used with mild sedation? Standardized pathways for escalating care in severe COPD exacerbations, along with further training—particularly scenario-based education for managing complex environments and anxious patients—can enhance paramedic readiness.

And what about epinephrine? As mentioned earlier, the evidence remains limited and often inconclusive. There are strong theoretical arguments both for and against the use of epinephrine, highlighting the need for further research in this area.

References